Kiełbasiński R

No ORCID on file · 4 papers in corpus · active 2019-2020

Study types

  • other 1
2020
Current pharmaceutical biotechnology ·doi:10.2174/1389201021666191227121627

BackgroundEndometrial cancer is one of the most common gynecological cancer in the developed countries and occurs mainly in postmenopausal women. Angiogenesis is important for cancer formation as it provides nutrients for growing tumor mass…

2019
Current pharmaceutical biotechnology ·doi:10.2174/1389201020666190619145655

BackgroundIn the course of neoplastic diseases, a reduction in SEMA3F expression is observed, which translates into an increase in the proliferative and proangiogenic potential of cells forming the tumor and the surrounding microenvironment…

other 2019
Current pharmaceutical biotechnology ·doi:10.2174/1389201020666190717092448

BACKGROUND: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. OBJECTIVES: The aim of the study w…

2019
Medical science monitor : international medical journal of experimental and clinical research ·doi:10.12659/msm.916762

BACKGROUND SEMA3B is known as an inhibitor of angiogenesis and cell proliferation. During carcinogenesis, the loss of SEMA3B function is observed, which results in the progression of neoplastic changes. The aim of this study was to evaluate…